☰

Mohammad S. Atefi, Ph.D. - Publications

Affiliations: 
2008 University of California, Los Angeles, Los Angeles, CA 
Area:
Molecular Biology, Oncology
Tree Info Similar researchers PubMed Report error

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, Wong DJL, Atefi M, Shirazi R, Wang X, Braas D, Grasso CS, Palaskas N, Ribas A, Graeber TG. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. PMID 29657129 DOI: 10.1016/J.Ccell.2018.03.017  0.414
2016 Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, Friedman M, Shi H, Moriceau G, Song C, Hong A, Atefi M, Li R, Komisopoulou E, Ribas A, et al. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discovery. 2: 16028. PMID 27648299 DOI: 10.1038/Celldisc.2016.28  0.396
2016 Escuin-Ordinas H, Li S, Xie MW, Sun L, Hugo W, Huang RR, Jiao J, de-Faria FM, Realegeno S, Krystofinski P, Azhdam A, Komenan SM, Atefi M, Comin-Anduix B, Pellegrini M, et al. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Nature Communications. 7: 12348. PMID 27476449 DOI: 10.1038/Ncomms12348  0.4
2016 Atefi M, Titz B, Tsoi J, Avramis E, Le A, Ng C, Lomova A, Lassen A, Friedman M, Chmielowski B, Ribas A, Graeber TG. CRAF R391W is a melanoma driver oncogene. Scientific Reports. 6: 27454. PMID 27273450 DOI: 10.1038/Srep27454  0.495
2015 Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Molecular Cancer. 14: 128. PMID 26134498 DOI: 10.1186/S12943-015-0393-2  0.367
2015 Atefi M, Titz B, Avramis E, Ng C, Wong DJ, Lassen A, Cerniglia M, Escuin-Ordinas H, Foulad D, Comin-Anduix B, Graeber TG, Ribas A. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Molecular Cancer. 14: 27. PMID 25645078 DOI: 10.1186/S12943-015-0293-5  0.506
2014 Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Molecular Cancer. 13: 194. PMID 25142146 DOI: 10.1186/1476-4598-13-194  0.495
2014 Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3446-57. PMID 24812408 DOI: 10.1158/1078-0432.Ccr-13-2797  0.363
2014 Wong DJ, Rao A, Avramis E, Matsunaga DR, Komatsubara KM, Atefi MS, Escuin-Ordinas H, Chodon T, Koya RC, Ribas A, Comin-Anduix B. Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunology Research. 2: 459-68. PMID 24795358 DOI: 10.1158/2326-6066.Cir-13-0188  0.438
2014 Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B, Ribas A. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Molecular Cancer. 13: 83. PMID 24735930 DOI: 10.1186/1476-4598-13-83  0.516
2014 Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Molecular Oncology. 8: 250-60. PMID 24345644 DOI: 10.1016/J.Molonc.2013.11.005  0.432
2013 Escuin-Ordinas H, Elliott MW, Atefi M, Lee M, Ng C, Wei L, Comin-Anduix B, Montecino-Rodriguez E, Avramis E, Radu C, Sharp LL, Ribas A. PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody. Journal For Immunotherapy of Cancer. 1: 14. PMID 24829750 DOI: 10.1186/2051-1426-1-14  0.309
2013 Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, et al. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 102-11. PMID 23377663 DOI: 10.1097/Cji.0B013E31827Bec97  0.337
2013 Wong DJ, Robert L, Atefi MS, Foulad D, Avramis EV, Comin-Anduix B, Samatar AA, Ribas A. Abstract 917: High antitumor activity of the ERK inhibitor SCH722984 against BRAF-mutant, NRAS-mutant and wild-type melanoma cell lines. Cancer Research. 73: 917-917. DOI: 10.1158/1538-7445.Am2013-917  0.483
2013 Atefi MS, Ng CP, Wong DJ, Robert L, Escuin-Ordinas H, Lassen A, Foulad D, Comin-Anduix B, Samatar AA, Ribas A. Abstract 915: Melanomas with rare BRAF mutations and their responses to MAPK pathway blocking drugs. Cancer Research. 73: 915-915. DOI: 10.1158/1538-7445.Am2013-915  0.505
2012 Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, et al. BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors Cancer Discovery. 2: 791-797. PMID 22798288 DOI: 10.1158/2159-8290.Cd-12-0097  0.416
2012 von Euw E, Atefi M, Attar N, Chu C, Zachariah S, Burgess BL, Mok S, Ng C, Wong DJ, Chmielowski B, Lichter DI, Koya RC, McCannel TA, Izmailova E, Ribas A. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Molecular Cancer. 11: 22. PMID 22515704 DOI: 10.1186/1476-4598-11-22  0.413
2012 Birkhäuser FD, Koya RC, Neufeld C, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Rampersaud EN, Chandramouli GV, Li G, Said JW, Ribas A, McBride WH, Kabbinavar FF, et al. Safety and efficacy of dendritic cell immunotherapy with ad-GMCAIX in an immunocompetent preclinical tumor model of renal cell carcinoma. Journal of Clinical Oncology. 30: e13045-e13045. DOI: 10.1200/Jco.2012.30.15_Suppl.E13045  0.375
2012 Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, et al. Abstract LB-428: RAS-independent dimerization of BRAF(V600E) splicing variants promotes resistance to RAF inhibitors Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-428  0.5
2012 Escuin-Ordinas H, Atefi M, Ng C, Sharp L, Ribas A. Abstract 361: PET imaging of antitumor responses with anti-4-1BB (anti-CD137) Cancer Research. 72: 361-361. DOI: 10.1158/1538-7445.Am2012-361  0.343
2012 Birkhäuser FD, Koya RC, Neufeld C, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Rampersaud EN, Chandramouli GV, Li G, Said JW, Ribas A, McBride WH, Kabbinavar FF, et al. Abstract 1563:In vivosafety and efficacy of a novel dendritic cell based Ad-GMCAIX vaccine with activity against renal cell carcinoma Cancer Research. 72: 1563-1563. DOI: 10.1158/1538-7445.Am2012-1563  0.405
2011 Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. Plos One. 6: e28973. PMID 22194965 DOI: 10.1371/Journal.Pone.0028973  0.491
2011 Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 480: 387-90. PMID 22113612 DOI: 10.1038/Nature10662  0.451
2011 Ribas A, Chodon T, Comin-Anduix B, Sondergaard J, Mok S, Ng C, Escuin-Ordinas H, Atefi M, Chmielowski B, Czernin J, Witte ON, Radu CG, Koya RC. Abstract SY03-04: Novel imaging approaches for immunotherapy and targeted therapy of melanoma in animal models and humans Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Sy03-04  0.411
2011 Euw Ev, Atefi M, Attar N, Zachariah S, Burgess BL, McCannel T, Lichter DI, Izmailova E, Ribas A. Abstract 3584: Effects of the investigational selective MEK inhibitor TAK-733 against cutaneous and uveal melanoma cell lines Cancer Research. 71: 3584-3584. DOI: 10.1158/1538-7445.Am2011-3584  0.489
2010 Atefi MS, Zheng C, Atefi Z, Slamon DJ. Abstract 4602: Effect of estrogen receptor antagonistic drugs on expression and regulation of fatty acid synthase (FAS) in ER+ breast cancer cell lines Cancer Research. 70: 4602-4602. DOI: 10.1158/1538-7445.Am10-4602  0.385
2009 Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research : Bcr. 11: R77. PMID 19874578 DOI: 10.1186/Bcr2419  0.338
Show low-probability matches.